PDLIM7 and post-transplant lymphoproliferative disease: Encouraged by the excellent results of treatment of PTLD with ACT, ACTs have been developed for NPC and HL using in vitro expanded CTLs targeting type II latency antigens EBNA1, LMP1 and LMP2 [(198, 199, 206–208), Table 3].